Skip to main content
. 2021 Feb 13;25(1):101544. doi: 10.1016/j.bjid.2021.101544

Table 3.

Results of line probe assay for second-line drugs among patients with MDR-TB.

Resistance mutations
Gene region
Not detectable
Detectable
N % n %
Fluoroquinolones 21 84.0 4 16.0 gyrA-D94G: 2;
gyrA-S91P: 1
gyrB-N538D: 1
Am/CM/VIO 25 100.0
KN (low level) 24 96.0 1 4.0

KN, kanamycin; Am, amikacin; CM, capreomycin; VIO, viomicin.